GlassScriptPhysician profile
Jaideep Debsikdar
NPI 1558308452
$4,851.88
in general payments reported to CMS, 2019-2025
25 companies · $21.40 in 2025
The $21.40 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $318 · 2021: $704 · 2022: $454 · 2023: $1,745 · 2024: $1,086 · 2025: $21.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,852.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $967.01 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $566.69 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $507.63 | 2019-2024 | Xarelto |
| Pfizer INC. | $464.50 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.63 | 2021-2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $221.69 | 2022-2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $199.92 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $167.73 | 2019-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $164.81 | 2019-2024 | Farxiga, Wainua |
| Amgen INC. | $151.20 | 2023-2024 | Repatha |
| Philips North America LLC | $150.75 | 2022-2024 | (Ck4) Mcot |
| Boston Scientific Corporation | $145.03 | 2023-2024 | Lux-Dx Insertable Cardiac Monitor, Bodyguardian |
| Novo Nordisk INC | $138.72 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $132.10 | 2019-2023 | |
| Scpharmaceuticals INC. | $94.23 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $51.42 | 2023-2024 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $50.64 | 2021-2022 | |
| Abbott Laboratories | $46.82 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $41.92 | 2023 | Optimizer |
| Cvrx, INC. | $34.62 | 2023 | Barostim Neo System |
| Cardiva Medical, INC. | $32.05 | 2024 | Optowire |
| Medtronic Vascular, INC. | $30.52 | 2020 | |
| Esperion Therapeutics, INC. | $15.14 | 2020 | |
| Janssen Scientific Affairs, LLC | $13.58 | 2024 | Xarelto |
| Arbor Pharmaceuticals, INC. | $13.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaideep Debsikdar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.